British Journal of Clinical Pharmacology · 1982 · 65 citations · 19 references
PharmacyPharmacokineticsPharmacologyBioavailabilityClinical PharmacologyDrug ClearanceBioavailability AnalysisBioavailability AssessmentBioavailability VariabilityDrug DispositionOral BioavailabilityApparent Absorption ClearanceLinear Elimination KineticsMean Absorption TimeOral Absorption AssessmentOral Drug Absorption VariabilityOral Drug BioavailabilityPharmacokinetic Parameters
1 The pharmacokinetics of dihydroergotamine (DHE) in plasma were examined in six normotensive subjects after single acute doses of dihydroergotamine, 10 micrograms/kg i.v. and 10, 20 and 30 mg orally. 2 The mean apparent half-time of elimination was 2.37 +/- 0.29 h and plasma clearance of dHE was 1002 +/- 169 ml/min. 3 Mean apparent absorption of DHE determined from the 10 mg dose was 26.6 +/- 10% and ranged from 8.9 to 60.3%. The oral bioavailability after the 10, 20 and 30 mg doses averaged 0.47 +/- 0.07%, 0.59 +/- 0.13% and 0.52 +/- 0.14% respectively. Inter-patient variability in bioavailability was 6-fold. 4 The results indicate that pre-systemic 'first-pass' extraction of DHE is the main determinant of its oral bioavailability. Oral doses of the drug up to 30 mg do not saturate this extraction process resulting in apparently linear kinetics for the drug.
19
Determination of norepinephrine apparent release rate and clearance in humans
Murray Esler, Graham P. Jackman, Alex Bobik et al. · Life Sciences · 1979 · 348 citations